Introduction {#S1}
============

Fibromyalgia syndrome (FMS) is a medical diagnosis of unknown etiology mainly characterized by chronic and widespread pain ([@B1]). Other symptoms include fatigue, gastrointestinal symptoms, and joint stiffness ([@B1]--[@B3]). Furthermore, a growing body of evidence shows a comorbidity of FMS with psychological symptoms, particularly with depression and anxiety ([@B2]--[@B9]): lifetime prevalence of depression and anxiety in patients with FMS go up to 70 and 60%, respectively ([@B8]). Widespread pain and mental disorders compose a relevant public health problem due to the high economic and societal burden ([@B10]--[@B13]). A better understanding of risk factors for the onset of depressive and anxious symptomatology in FMS might, therefore, be instrumental in identifying strategies for prevention and early interventions, such as those recommended by the European League Against Rheumatism (EULAR) ([@B14], [@B15]). Risk factors for the onset of depression and anxiety have been studied longitudinally, and include pain, a negative perception of health, dysfunctional coping strategies, personality traits (e.g., neuroticism), female gender, and lower education ([@B10], [@B16]). This study will focus on those factors that have shown to be associated with an increased risk of depression and anxiety in chronic pain patients, and that might be easily modifiable in treatment: severity of pain ([@B10], [@B17]--[@B20]), coping strategy ([@B21]--[@B23]), and illness perceptions ([@B24]--[@B26]). To date, longitudinal studies exploring the contribution of all these risk factors in subsequent depressive and anxious symptomatology in patients with FMS in one study are lacking.

Widespread pain is characteristic for FMS ([@B1]) and thorough research exists exploring the association of widespread pain and severity of pain with depressive and anxiety disorders ([@B10], [@B17]--[@B20]). In several cross-sectional studies, among which a review and a large survey among 17 countries, multiple pain locations were more strongly associated with depression and anxiety when compared with one pain location and no pain ([@B10], [@B17], [@B18]). In two longitudinal studies, every additional pain location increased the risk of a new onset and recurrence of a depressive and/or anxiety disorder with 29 and 7%, respectively ([@B19], [@B20]). Moreover, for every increase in the severity of pain the risk increased with 57% for new onset and 11% for recurrence of depression and/or anxiety ([@B19], [@B20]).

Another risk factor associated with depression and anxiety is coping style. Patients with FMS tend to cope passively, such as catastrophizing ([@B27], [@B28]). In patients with FMS, pain is indirectly associated with depression through its relationship with a passive coping style ([@B21]). A passive coping style, in turn, is significantly associated with depression ([@B27]). Furthermore, in studies among patients with other rheumatic diseases, passive coping strategies, including withdrawal and worrying or catastrophizing, were also associated with psychological distress ([@B22], [@B23]).

A maladaptive coping style is associated with poor illness perceptions ([@B29]), that in turn are associated with depressive and anxiety symptoms ([@B24]--[@B26], [@B29], [@B30]). In patients with chronic widespread pain, negative beliefs about their illness, such as that the illness would affect their emotional well-being, were found to be associated with an increase of depressive and anxious symptomatology ([@B24], [@B25]). Also, patients with rheumatoid arthritis who had negative beliefs about the consequences of their illness were more depressed over time ([@B26]).

Patients with FMS are characterized by pain in multiple locations, or widespread pain. This makes them vulnerable for depression and anxiety. However, it is unknown whether other characteristics are associated with the onset of depression and anxiety. Cross-sectional studies suggest that more severe pain, a maladaptive (passive) coping style, and negative illness perceptions are related to depression and anxiety in patients with (chronic) pain and in patients with rheumatic diseases ([@B17], [@B18], [@B21]--[@B25]). FMS is a rheumatic disease, characterized by chronic pain, which makes it likely that these factors would also play a role in the onset and persistence of depressive and anxious symptomatology in this population. However, these factors have not been studied in concert and longitudinally in FMS before. Therefore, a study exploring this association in a longitudinal design in FMS is warranted. The aim of this study is to examine pain, pain-related coping, and illness perception as possible risk factors for depressive and anxious symptomatology in patients with FMS. We hypothesize that more pain, passive pain-related coping and poor illness perceptions at baseline are associated with more depressive and anxiety symptoms in FMS.

Materials and Methods {#S2}
=====================

Study Design {#S2-1}
------------

This study used data from an observational, prospective cohort study, with follow-up every 6 months for up to 18 months. Not all questionnaires of interest were used at every follow-up measurement, and, therefore, the baseline and 18-month data were used for this study.

Setting {#S2-2}
-------

Data were collected of newly referred consecutive patients to the Sint Maartenskliniek rheumatology outpatient clinic, location Nijmegen and Woerden, the Netherlands, between December 2011 and November 2014.

Ethics Statement {#S2-3}
----------------

This study was carried out in accordance with the recommendations of the local medical ethical board with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The Institutional Review Board of the University Medical Centre, Nijmegen, approved the study (protocol number: 2011/271).

Participants {#S2-4}
------------

Patients were included in the cohort after being classified as having FMS by certified rheumatologists, who followed the ACR guidelines ([@B31], [@B32]) as a diagnostic aid. Other inclusion criteria were being 18 years or older and to be able to read and write in the Dutch language. There were no exclusion criteria next to these inclusion criteria. A total of 452 patients with FMS were eligible for inclusion, 311 gave informed consent (68.8%), and subsequently, 280 patients returned the baseline questionnaire (90.0%). Most frequent dropout reasons were lack of energy or concentration, and lack of time. Several patients did not specify a reason. For this study, all 280 participants were included. See Figure [1](#F1){ref-type="fig"} for a flowchart.

![Flowchart of the inclusion procedure.](fpsyt-08-00217-g001){#F1}

Variables {#S2-5}
---------

### Dependent Variables {#S2-5-1}

The primary outcomes were the presence of depressive symptoms (yes/no) and the presence of anxiety symptoms (yes/no). Anxiety and depressive symptomology were assessed using the self-rated, 14-item Hospital Anxiety and Depression Scale (HADS) ([@B33]), which scores the severity of depressive (HADS-D) and anxiety (HADS-A) symptoms, both subscales ranging from 0 to 21. This measure was developed specifically for medically ill populations and excludes bodily symptoms such as sleep disturbance, fatigue, and pain that may be directly attributable to the physical illness ([@B33]). The HADS has been widely used in people with medical illnesses, and its factor structure has been confirmed ([@B34]--[@B36]). The presence of depressive and anxiety symptoms was defined using the cutoff scores of ≥8 for "possible/probable" depressive or anxiety disorder ([@B33]). The cutoff score of 8 or more for both subscales has shown good predictive value for depressive and anxiety disorders, in somatic, psychiatric, and primary care patients, as well as in the general population ([@B37]). Both subscales of the HADS have a good internal consistency (Cronbach's alpha for HADS-D ranges from 0.67 to 0.90; Cronbach's alpha for HADS-A ranges from 0.68 to 0.93) ([@B37]).

### Predictor Variables {#S2-5-2}

#### Pain {#S2-5-2-1}

Pain was assessed using the pain severity subscale of the Dutch translation of the Fibromyalgia Impact Questionnaire (FIQ) ([@B38], [@B39]), ranging from 0 (no pain) to 10 (severe pain). Reliability and validity of the FIQ are good ([@B38]).

#### Pain Coping {#S2-5-2-2}

Pain coping was measured using the Pain Coping Inventory (PCI) ([@B40]). The PCI consists of six scales (33 items) measuring cognitive and behavioral pain-coping strategies that represent two higher order, active, and passive pain-coping dimensions. Items are rated according to a 4-point Likert scale ranging from 1 (hardly ever) to 4 (very often) in terms of frequency with which strategies are applied when dealing with pain. Active pain-coping strategies reflect three cognitive-behavioral strategies, measuring patient's efforts to distract themselves from pain (distraction, five items), to reinterpret and transform the pain (pain transformation, four items), and to function despite pain (reducing demands, three items). Passive pain coping reflects three cognitive-behavioral strategies, assessing behavioral tendencies to restrict functioning (resting, five items), to avoid environmental stimuli (retreating, seven items), and catastrophic cognitions about the pain (worrying, nine items). A composite score of the active and passive coping dimensions can be calculated by taking the mean of the three active and passive coping strategies. Confirmatory construct and criterion validity of the scales and the second-order structure with respect to active and passive pain-coping strategies were supported ([@B40], [@B41]).

#### Illness Perception {#S2-5-2-3}

Participants completed the Revised version of the Illness Perception Questionnaire (IPQ-R) ([@B42]), which assesses patients' perception of their illness. The following seven dimensions of the IPQ-R were included: Timeline (e.g., "My illness will last a short time"), Timeline cyclical (e.g., "My symptoms come and go in cycles"), Consequences (e.g., "My illness is a serious condition"), Personal control (e.g., "Nothing I do will affect my illness"), Treatment control (e.g., "My treatment will be effective in curing my illness"), Illness coherence (e.g., "I do not understand my illness"), and Emotional representations (e.g., "My illness makes me feel angry"). The IPQ-R is a reliable and well-validated self-report questionnaire ([@B42]--[@B44]).

#### Covariates {#S2-5-2-4}

Initial levels of depressive and anxiety symptoms play an important role in subsequent depressive and anxious symptomatology ([@B20], [@B45]). Therefore, baseline HADS-D score (initial level of depressive symptoms) and baseline HADS-A score (initial level of anxiety symptoms) were inserted in the statistical models as covariates.

### Sociodemographic Variables {#S2-5-3}

Assessed sociodemographic variables were as follows: sex, age, partner status, and education level (primary/lower secondary and higher secondary/professional).

Statistical Methods {#S2-6}
-------------------

Descriptive statistics were performed to describe the sample at baseline, regarding sociodemographic variables, pain severity, pain coping, illness perceptions, and depressive and anxiety symptoms. To examine which variables predicted depressive (*n* = 68) and anxiety symptoms (*n* = 80) at 18-month follow-up, the following steps were performed: (1) selection of potential variables: univariate logistic regression analyses were performed, with *p* \< 0.05 as a selection criterion for potential predictive variables; (2) multivariable logistic regression analyses using backward selection (stopping rule *p* \< 0.2); (3) internal validation with a bootstrap procedure (500 samples) to estimate the amount of over-fit; and (4) through calibration, the slope value was calculated and used to correct and shrink the regression coefficients, the percentage of explained variance (*R*^2^), and the *c*-index. Initial level of depressive symptoms and initial level of anxiety symptoms were inserted in the models as covariates, and their association with the outcome variables was shown when significant. The models' performance was assessed by the percentage of variance; the agreement between the predicted probabilities of the outcome and the observed probabilities in the original data (*p* \> 0.05; i.e., Hosmer--Lemeshow test); and by the models' discriminative ability \[as reflected by the *c*-index that equals the area under the receiver operating characteristic curve (AUC)\].

Results {#S3}
=======

Table [1](#T1){ref-type="table"} shows the baseline characteristics of the 280 persons in this cohort. Mean age of the study sample was 42.6 years, and 95.4% were female. Mean pain severity was 6.75 on a 10-point Likert scale. Of the participants, 118 (42.1%) had a possible or probable depressive disorder, and 140 (50%) had a possible or probable anxiety disorder at baseline.

###### 

Sociodemographic variables, pain severity, pain-coping strategies, and illness perceptions of the fibromyalgia cohort at baseline (*N* = 280).

  ----------------------------------- ----------------- ---------------
  Sex (*N*, %)                        Male              13 (4.6)
  Female                              267 (95.4)        
                                                        
  Age (mean, SD)                                        42.61 (11.83)
                                                        
  Education level (*N*, %)            Low               122 (44)
  Middle                              95 (34)           
  High                                55 (20)           
                                                        
  Marital status (*N*, %)             Without partner   59 (21.1)
  With partner                        218 (77.9)        
                                                        
  Pain severity (mean, SD)                              6.75 (2.09)
  Pain-coping strategies (mean, SD)   Passive           43.83 (7.97)
  Active                              29.16 (4.93)      
                                                        
  Illness perceptions (mean, SD)      Timeline          23.71 (4.26)
  Consequences                        19.86 (4.26)      
  Personal control                    20.34 (3.66)      
  Treatment control                   17.00 (2.88)      
  Illness coherence                   15.00 (4.09)      
  Timeline cyclical                   14.69 (3.27)      
  Emotional representations           15.76 (4.74)      
                                                        
  HADS depression (*N*, %)            Normal            162 (57.9)
  Possible/probable depression        118 (42.1)        
                                                        
  HADS anxiety (*N*, %)               Normal            139 (50.0)
  Possible/probable anxiety           140 (50.0)        
  ----------------------------------- ----------------- ---------------

*HADS, Hospital Anxiety and Depression Scale*.

Table [2](#T2){ref-type="table"} shows the univariate associations between all predictor variables and the covariates, with depressive and anxious symptomatology at 18-month follow-up (*n* = 68 for depressive symptoms; *n* = 80 for anxiety symptoms). Regarding the depression outcome, a passive coping style (OR = 2.92), and the IPQ subscales "timeline" (OR = 1.09), "consequences" (OR = 1.22), "personal control" (OR = 0.89), and "emotional representations" (OR = 1.19) had a significant univariate association with a possible/probable depressive disorder at 18-month follow-up. The covariates' initial level of depressive symptoms and initial level of anxiety symptoms also had a significant univariate association with a possible/probable depressive disorder at 18-month follow-up (OR = 1.37 and OR = 1.21, respectively). After logistic regression with backward selection (Table [3](#T3){ref-type="table"}), the IPQ subscale "emotional representations" (OR = 1.10) was significantly associated with possible/probable depressive disorder at 18-month follow-up, next to initial level of depressive symptoms (OR = 1.30). Thus, subjects who respond emotionally regarding their illness and have more initial depressive symptoms at baseline are at increased risk for a possible or probable depressive disorder at follow-up. Together, these variables in the regression model accounted for 30% of the variance of the depression score at follow-up. The overall fit of the derived model was good (χ^2^ = 13.85, *p* = 0.09).

###### 

Univariate logistic regression analyses of sociodemographics, pain severity, coping strategies, and illness perceptions, for depressive and anxiety symptoms.

                                   HADS depression (*n* = 68)                          HADS anxiety (*n* = 80)
  -------------------------------- --------------------------------------------------- ---------------------------------------------------
  **Sociodemographics**                                                                
  Sex                              1.06 (0.26--4.36)                                   1.39 (0.34--5.74)
  Age                              1.00 (0.98--1.03)                                   0.98 (0.96--1.01)
  Having a partner                 0.84 (0.41--1.70)                                   0.75 (0.38--1.49)
  Higher educational level         0.61 (0.30--1.24)                                   0.62 (0.32--1.21)
  Pain severity                    1.15 (0.99--1.33)                                   1.13 (0.98--1.30)
  **Coping strategy**                                                                  
  Active coping                    0.54 (0.26--1.13)                                   0.60 (0.30--1.20)
  Passive coping                   2.92 (1.27--6.73)[\*](#tfn1){ref-type="table-fn"}   2.80 (1.23--6.35)[\*](#tfn1){ref-type="table-fn"}
  **Illness perceptions**                                                              
  Timeline                         1.09 (1.01--1.17)[\*](#tfn1){ref-type="table-fn"}   1.06 (0.99--1.14)
  Timeline cyclical                0.93 (0.85--1.02)                                   1.03 (0.94--1.12)
  Consequences                     1.22 (1.12--1.33)[\*](#tfn1){ref-type="table-fn"}   1.17 (1.08--1.26)[\*](#tfn1){ref-type="table-fn"}
  Personal control                 0.89 (0.81--0.97)[\*](#tfn1){ref-type="table-fn"}   0.94 (0.86--1.02)
  Treatment control                0.91 (0.81--1.01)                                   0.90 (0.81--0.99)[\*](#tfn1){ref-type="table-fn"}
  Illness coherence                0.96 (0.89--1.03)                                   0.95 (0.89--1.02)
  Emotional representations        1.19 (1.10--1.28)[\*](#tfn1){ref-type="table-fn"}   1.19 (1.10--1.28)[\*](#tfn1){ref-type="table-fn"}
  **Covariates**                                                                       
  HADS baseline depression score   1.37 (1.24--1.52)[\*](#tfn1){ref-type="table-fn"}   1.21 (1.11--1.32)[\*](#tfn1){ref-type="table-fn"}
  HADS baseline anxiety score      1.21 (1.12--1.32)[\*](#tfn1){ref-type="table-fn"}   1.44 (1.30--1.61)[\*](#tfn1){ref-type="table-fn"}

*HADS, Hospital Anxiety and Depression Scale*.

*\*Significant at the 0.05 level*.

###### 

Multivariable logistic model predicting depressive and anxiety symptoms at 18-month follow-up.

                                           HADS depression (*n* = 68)   HADS anxiety (*n* = 80)                  
  ---------------------------------------- ---------------------------- ------------------------- -------------- ---------------
  HADS baseline depression score           1.30                         \<0.0001                                 
  HADS baseline anxiety score                                                                     1.45           \<0.0001
  Treatment control                                                                               0.87           0.04
  Emotional representations                1.10                         0.03                                     
                                                                                                                 
  **Model performance**                    **Model**                    **Corrected**             **Model**      **Corrected**
                                                                                                                 
  Explained variance (Nagelkerke *R*^2^)   0.35                         0.30                      0.44           0.40
  *c*-Index                                0.82                         0.80                      0.85           0.83
                                                                                                                 
  **Calibration**                                                                                                
  Hosmer and Lemeshow                      χ^2^ = 13.85                                           χ^2^ = 13.05   
  Slope value                              0.89                                                   0.90           

*HADS, Hospital Anxiety and Depression Scale*.

Regarding anxiety outcome, a passive coping style (OR = 2.80), and the IPQ subscales "consequences" (OR = 1.17), "treatment control" (OR = 0.90), and "emotional representations" (OR = 1.19) had a significant univariate association with a possible/probable anxiety disorder at 18-month follow-up (Table [2](#T2){ref-type="table"}). The covariates' initial level of depressive symptoms and initial level of anxiety symptoms also had a significant univariate association with a possible/probable anxiety disorder at 18-month follow-up (OR = 1.21 and OR = 1.44, respectively). After logistic regression with backward selection, treatment control (OR = 0.87) was significantly associated with possible/probable anxiety disorder at 18-month follow-up, next to initial level of anxiety symptoms (OR = 1.45) (Table [3](#T3){ref-type="table"}). Thus, subjects who think that their treatment is not effective regarding their illness and have more anxiety symptoms at baseline are at increased risk for a possible or probable anxiety disorder. Together, these variables in the regression model accounted for 40% of the variance of the anxiety score at follow-up. The overall fit of the derived model was good (χ^2^ = 13.05, *p* = 0.11).

Discussion {#S4}
==========

To the authors' knowledge, this is the first study to document on pain, illness perception, and coping style as risk factors for depressive and anxious symptomatology in patients with FMS. The results here indicate that patients with FMS who believe their illness will have a negative effect on their mental well-being, who also have elevated levels of depressive symptoms, are more likely to be depressed on subsequent occasions. Furthermore, patients with FMS who think that treatment of their illness will not be effective and who also have elevated levels of anxiety symptoms are more likely to be anxious on subsequent occasions. Our hypothesis that poor illness perceptions are a risk factor for depressive and anxious symptomatology is therefore confirmed.

Only illness perceptions and initial level of affective symptoms were found to play a significant role in depressive and anxious symptomatology, suggesting that these factors are possibly more important than other well-known risk factors, such as pain, which is contrary to what we expected. These findings are consistent with previous research in similar populations. For example, patients with chronic (widespread) pain who had a strong belief that their illness would affect their mental well-being were more likely to report depressive and anxiety symptoms ([@B24], [@B25]), whereas pain intensity did not show such an association ([@B24]). In patients with rheumatoid arthritis, the patients' beliefs and emotional responses to their illness were key factors explaining the association between pain and depression ([@B46]). Furthermore, in two large longitudinal studies, the association between pain and new onset and recurrence of depression and anxiety were mediated by (subthreshold) depressive symptoms ([@B19], [@B20]). This could explain our finding that not pain severity, but negative cognitions about the illness and the initial level of affective symptoms are more important as risk factors in the development of subsequent depressive and anxious symptomatology. Neurobiological abnormalities might also play a role, which persists in patients who have experienced strong negative emotions, possibly through negative biases in the processing of emotional information ([@B47]). On the other hand, pain and emotion share neuronal networks, and pain, one of the main characteristics of FMS, might cause a dysregulation in the neuronal network associated with emotion ([@B48]). Thus, patients with FMS who experience negative affective symptoms and negative perceptions regarding their illness might, therefore, have developed neurobiological abnormalities, making them vulnerable for subsequent depressive and anxious symptomatology.

Contrary to what we expected, a passive coping style was not a significant risk factor for depressive and anxiety symptoms, in contrast to a previous study in patients with FMS ([@B21]). However, they used another construct of passive coping, emphasizing on emotion-focused strategies, whereas passive coping in this study was mostly characterized by avoidant strategies. In a study in patients with systemic sclerosis, a rheumatic disease, emotion-focused coping had a strong association with depressive symptoms, whereas avoidant focused coping did not ([@B22]). Furthermore, in patients with chronic heart failure, an avoidant coping style was indirectly associated with depression and anxiety through poor illness perceptions ([@B29]), which might explain our findings. This might suggest that emotional components of coping with an illness are more important than other maladaptive forms of coping. In our study, passive coping consisted of three cognitive-behavioral strategies, one of them being catastrophizing or worrying, which is an emotional component also. Therefore, future studies should explore the subcategories of passive coping to explore whether the emotional components of coping are indeed more important than other components.

Strengths of this study are the longitudinal design and the large sample size. However, several limitations need to be addressed. The sample of this study consisted of patients with FMS, which limits the generalizability to other populations. However, comparable results were found in other rheumatologic populations ([@B22], [@B24], [@B25], [@B46]). This might suggest that our results are generalizable to populations characterized by a chronic disease. In this study, the HADS, which was developed specifically for medically ill populations, was used to measure depressive and anxious symptomatology. Although this instrument has good internal consistency and can be used as case finding for depressive and anxiety disorders ([@B37]), and is widely used in rheumatologic populations, no inferences could be made whether patients met criteria for a depressive or anxiety disorder. For such purposes, diagnostic (semi)structured interviews need to be used, such as the Mini-International Neuropsychiatric Interview ([@B49]) or Composite International Diagnostic Interview ([@B50]). In addition, we used a single self-reported questionnaire (FIQ) to measure pain severity, which prevents us to make inferences of other aspects of functioning and well-being, such as quality of life. Besides, it is possible that factors not studied here might play a crucial role in depressive and anxious symptomatology in patients with FMS. Received treatment, whether it is physical ([@B51]--[@B54]), psychological, or pharmacological ([@B55]), can influence both depressive as anxiety symptoms. Patients in this study received advice for treatment, based on the recommendations of the EULAR ([@B14], [@B15]), after the baseline measurement. Treatment advice could be referral (back) to the general practitioner, physiotherapist, psychologist, or a multimodal rehabilitation program. Unfortunately, no information was available whether this advice was followed, or if another treatment was received other than advised. We were, therefore, unable to make any inferences on the effect of treatment on depression and anxiety. Other factors that might influence depressive and anxious symptomatology are medication use, comorbidity with other chronic diseases ([@B56]), and perceived social support ([@B57]). Unfortunately, due to the limited sample size at follow-up (68 patients for depressive symptoms and 80 for anxiety symptoms), it was not possible to include more factors in the statistical models. Future research with larger sample sizes is needed. A larger sample size is also necessary to examine the incidence of depressive and anxious symptomatology, by excluding those patients with depressive and anxiety symptoms at baseline. The sample size of this study was too small, unfortunately.

Conclusion {#S5}
==========

Our study highlights the importance of illness perceptions in the development of depressive and anxious symptomatology in patients with FMS. Developing treatment interventions aimed at modification of poor illness perceptions is therefore of interest. It has been shown that interventions focusing on illness perceptions, such as cognitive treatment and illness perception focused intervention, is effective in improving maladaptive perceptions in patients with chronic low back pain ([@B58]), and even has a positive effect on depressive and anxious symptomatology ([@B59]). In addition, cognitive behavior therapy focusing on catastrophizing has shown to be effective at increasing acceptance of the illness and global functioning in patients with FMS ([@B60]). Our findings corroborate the recommendations of the EULAR for psychological treatment, such as cognitive behavior therapy, in case of depressed mood ([@B15]). Thus, strengthening illness beliefs and reducing catastrophic thinking seem to be important factors in the treatment of patients with FMS, allowing them to improve their health. Future research should further explore the effects of such interventions.
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